As of June 2025, ZTS's trailing twelve months (TTM) EPS stands at $5.58, according to the latest financial reports. In 2024, the company recorded an earnings per share (EPS) of $5.47, which represents an increase compared to its EPS of $5.08 in 2023. ZTS reported an EPS of $1.41 for the quarterly report ending on Mar 31, 2025.
For 2024, Zoetis's EPS was $5.47, an increase of 7.7% from $5.08 in 2023. For the quarter ending Mar 31, 2025, the EPS was $1.41, showing a 7.6% increase from the same quarter last year. The trailing twelve months (TTM) EPS as of March 2025 is $5.58. In 2023, the annual EPS was $5.08, showing an increase of 12.6% from 2022.
Zoetis has recorded an increase in EPS of 7.6% over the last 12 months (YoY, quarterly). For the last three years, ZTS recorded an average annual EPS growth rate of 8.4%. Zoetis had an average annual EPS growth rate of 11.7% over the last 5 years. Across the last decade, ZTS had an average annual EPS growth of 16.8%.
Stock name | Price to Earnings | EPS grwoth 1Y | EPS grwoth 3Y | EPS grwoth 5Y |
---|---|---|---|---|
MRK Merck & Co Inc | 11.45 | 4,728.6% | 9.4% | 12% |
PFE Pfizer Inc | 16.85 | 273.7% | -28.7% | -13.2% |
PAHC Phibro Animal Health Corp | 30.35 | -92.6% | -64.5% | -46.4% |
ZTS Zoetis Inc | 30.44 | 7.7% | 8.4% | 11.7% |
LLY ELI LILLY & Co | 62.21 | 102.1% | 24.1% | 5.7% |
ICCC Immucell Corp | N/A | 65.3% | N/A | N/A |
All data is based on quarterly TTM periods, unless otherwise specified.